Five Medtech Trends Shaping Global Healthcare in 2026

The global medical technology (medtech) industry is entering a period of accelerated structural change. Across pricing, care delivery, supply chains, clinical pathways, and enabling technologies, five trends are poised to reshape markets, business models, and strategic priorities worldwide. This analysis explores each trend’s international significance, economic implications, and long-term consequences for healthcare systems, multinational corporations, and investors.

Executive Summary

Medical technology companies face a convergence of market forces that will define competitiveness in 2026 and beyond. Mainland China’s volume-based procurement (VBP) expansion is extending its influence far beyond its borders, pressuring global pricing expectations and accelerating domestic innovation. Simultaneously, the migration of procedures to outpatient and ambulatory surgical centers (ASCs) is transforming the economics of care delivery in the United States and other mature markets. Global trade and supply chain pressures are compelling manufacturers to diversify production and rethink sourcing strategies. The meteoric rise of GLP-1 receptor agonists is changing patient behavior and disrupting procedure volumes across several therapeutic areas. Finally, enabling technologies—robotics, imaging, navigation, and digital workflows—are moving medtech competition from individual products to integrated platforms. These trends demand strategic responses from policymakers, industry leaders, and investors.

Introduction

The medical technology sector has long been characterized by innovation-driven growth and resilient demand. Yet the industry now faces an unusually broad set of structural forces that extend beyond clinical considerations. Demographic shifts, regulatory changes, macroeconomic pressures, and technological convergence are reshaping the competitive terrain. As governments grapple with healthcare affordability and providers seek more cost-effective delivery models, medtech companies must navigate an increasingly complex global environment. The trends outlined here represent not isolated phenomena but interlocking developments that together define the next phase of the industry’s evolution.

Background & Context

From Hospital-Centric to Distributed Care

For decades, medical technology innovation was primarily oriented toward hospital-based procedures and specialists. However, the global shift toward value-based care and cost containment has accelerated the migration of procedures to outpatient settings. The U.S. Centers for Medicare & Medicaid Services (CMS) has progressively expanded the list of procedures eligible for reimbursement in ambulatory surgical centers, reflecting a broader trend that is also occurring in Europe, Asia, and other regions. This evolution changes where and how devices are used, and alters the economic value proposition for both providers and manufacturers.

The Globalization of Procurement Reforms

China’s volume-based procurement program, launched in 2018, was initially designed to lower drug and device prices by leveraging the country’s massive market scale. Over successive rounds, VBP has evolved into an sophisticated instrument of industrial and health policy, with rules that favor domestic manufacturers while compressing prices for all participants. Its impact is no longer confined to China; multinational companies are increasingly using VBP-driven price benchmarks as reference points in other markets, creating a deflationary ripple effect internationally.

Supply Chain Vulnerabilities Exposed

The COVID-19 pandemic revealed the fragility of concentrated global supply chains, particularly in the production of critical components and raw materials used in medical devices. Geopolitical tensions, tariff disputes, and trade restrictions have further heightened these vulnerabilities. Medtech companies are now reassessing their manufacturing footprints, seeking to balance cost efficiency with resilience through multi-region strategies and increased use of advanced technologies.

The Metabolic Revolution

The rapid adoption of glucagon-like peptide-1 (GLP-1) receptor agonists—originally developed for diabetes—has transformed the management of obesity and related comorbidities. These therapies have become a global phenomenon, influencing clinical practices and patient decisions in areas far beyond endocrinology. Their impact on device-related procedures, from bariatric surgery to cardiovascular monitoring, is a case study in how pharmacological advances can disrupt adjacent sectors.

The Rise of Integrated Technology Platforms

Medtech innovation increasingly involves the convergence of hardware, software, and data analytics. Robotics, intraoperative imaging, navigation systems, and digital workflow tools are being integrated into comprehensive platforms that support entire clinical service lines. This platform-based approach offers new opportunities for differentiation and customer engagement but also raises questions about data ownership, interoperability, and market concentration.

Main Analysis

1. China’s VBP Expansion Redefines Global Market Economics

Mainland China’s latest national volume-based procurement round represents one of the most consequential shifts in global medtech pricing. The program, which began as a mechanism to improve patient access and reduce costs, has matured into a powerful instrument for reshaping the competitive landscape. Recent rules introduce more nuanced anchor-price logic, deeper price cuts, and allocation systems that explicitly support domestic manufacturers.

International Impact: Multinational medtech companies can no longer treat China’s VBP as a localized regulatory issue. The prices established in China’s procurement rounds increasingly serve as reference points for negotiations in other emerging markets and even in mature economies as payers seek value benchmarks. The program also accelerates the rise of domestic competitors who, backed by favorable policies, are expanding both within China and into global markets.

Strategic Implications: To remain viable in China, multinationals must recalibrate their portfolio strategies and cost structures. This may involve developing locally tailored products, forming domestic partnerships, or concentrating on premium segments less exposed to VBP. Conversely, they can leverage insights from China’s digital healthcare ecosystem to compete more effectively elsewhere. The long-term effect is likely to be a bipolar market structure, with high-volume basic devices dominated by domestic firms and advanced, high-technology products remaining a stronghold for foreign players.

2. Outpatient and ASC Settings Become Central to Procedure Strategy

The continued migration of procedures from hospital inpatient settings to outpatient facilities such as ambulatory surgical centers is accelerating. The CMS 2026 Hospital Outpatient Prospective Payment System (OPPS) and ASC Payment System Final Rule expands the ASC Covered Procedure List and phases out the inpatient-only list, allowing higher-acuity procedures like cardiac ablation to be performed in lower-cost settings.

International Impact: While most pronounced in the United States, this trend is also evident in other advanced economies where health systems are seeking to reduce costs and improve patient satisfaction. There is a growing recognition that many procedures previously considered too complex for outpatient settings can be safely and effectively performed there, thanks to technological advances in anesthesia, imaging, and minimally invasive techniques.

Strategic Implications: For medtech manufacturers, the shift to ASCs demands new commercial models and value propositions. ASCs are typically more price-sensitive and require devices that are easy to use, safely handled outside full hospital settings, and align with reimbursement realities. Product development must therefore consider not only clinical outcomes but also site-of-care economics. Providers and device makers together will need to identify which procedures benefit most from migration and how to support the transition.

3. Global Trade and Supply Chain Pressures Reshape Manufacturing Strategy

Trade tensions, tariffs, and geopolitical instability are challenging long-held assumptions about where and how medical devices are produced. Companies that had embraced lean, geographically concentrated supply chains are now investing in resilience, diversification, and flexibility.

International Impact: The cost and availability of critical materials, from semiconductors to specialized polymers, have become strategic variables. Disruptions in one region can have immediate effects worldwide, as the pandemic demonstrated. Moreover, tariff policy can alter the competitiveness of entire manufacturing hubs, prompting shifts in investment patterns.

Strategic Implications: Leading medtech players are building multi-region manufacturing footprints to mitigate risk. This involves not just adding capacity but also developing alternative suppliers and using digital tools such as predictive analytics to manage inventory more effectively. For smaller companies, the challenge is greater, and partnerships or contract manufacturing arrangements may become more important. As supply chain resilience becomes a differentiator, firms that master it may gain a competitive advantage beyond mere cost.

4. GLP-1 Therapies Shift Patient Behavior and Reshape Care Pathways

The explosive growth of GLP-1 receptor agonists has profound implications for medical technology. While bariatric surgery remains the most effective treatment for severe obesity, GLP-1s have expanded the options for weight management, affecting referral patterns and the timing and volume of interventions.

International Impact: This is a global phenomenon, with GLP-1 drugs approved in numerous countries. In markets where access is high, such as the US, Europe, and parts of the Middle East, the use of these therapies is altering clinical pathways across multiple specialties. Downstream effects are being felt in diabetes care, sleep apnea, cardiovascular disease, and chronic kidney disease, creating both challenges and opportunities for device manufacturers.

Strategic Implications: For companies focused on procedures like bariatric surgery, the growth of GLP-1s may require adjustments to their product portfolios and marketing strategies. There is also potential for synergies: devices used to monitor patients on GLP-1 therapies, such as continuous glucose monitors, may see increased demand. Medtech firms must understand the dynamics of metabolic disease management and collaborate with pharmaceutical companies to develop integrated solutions that address patient needs over the long term.

5. Enabling Technologies Drive Platform-Based Competition

Robotics, imaging, navigation, and digital workflow software are no longer add-ons to core procedures; they are becoming the foundation of integrated clinical ecosystems. Companies are investing in platforms that span the entire surgical journey, from pre-operative planning to intraoperative execution and post-operative management.

International Impact: These platforms are global in scope, with leading systems being deployed in hospitals and ASCs around the world. They produce vast amounts of data that can be used to improve care protocols and drive operational efficiencies. However, the concentration of these technologies in a few large companies raises questions about competition, interoperability, and healthcare equity.

Strategic Implications: Medtech firms need to make strategic choices about partnering, building, or acquiring capabilities in robotics and digital health. Platform ecosystems foster deeper customer relationships and create switching costs that protect market positions. At the same time, open-platform systems and interoperability standards may emerge, offering opportunities for niche players to plug into larger ecosystems. The race to create the dominant platform is underway, with long-term strategic consequences.

International Impact

The five trends analyzed above are not isolated; they interact to reshape the global medtech landscape in several key ways.

• Pricing and Market Access: The globalization of procurement reforms, combined with supply chain pressures, is compressing prices across many product categories. This creates challenges for innovation funding and may accelerate industry consolidation.
• Care Delivery Transformation: The migration to outpatient settings and the impact of GLP-1 therapies are fundamentally changing how and where care is provided. This requires new collaborations between providers, payers, and industry.
• Geopolitical and Economic Fragmentation: Trade and supply chain issues highlight the increasing interplay between healthcare and geoeconomics. Companies must navigate divergent regulatory regimes and industrial policies across major markets.
• Technology Convergence: The integration of enabling technologies into platforms is creating new competitive dynamics that transcend traditional device categories, bringing medtech into the digital realm.

For governments and international organizations, these trends underscore the need for policies that balance innovation, affordability, and resilience. For investors, they indicate that success in the medtech sector increasingly requires deep strategic analysis of market-specific developments and long-term structural shifts.

Strategic Perspectives

For Businesses

Multinational medtech companies should adopt a multi-dimensional approach:

• Portfolio Optimization: Re-evaluate product portfolios in light of China’s VBP and other pricing pressures, focusing on areas of high innovation and clinical differentiation.
• Site-of-Care Strategy: Develop tailored value propositions for ASCs and outpatient settings, including appropriate product design and pricing models.
• Supply Chain Transformation: Diversify manufacturing and sourcing, invest in digital supply chain visibility, and build resilience against geopolitical shocks.
• Adjacent-market Positioning: Monitor the GLP-1 effect and seek opportunities to complement pharmaceutical therapies with appropriate devices and monitoring solutions.
• Platform Development: Invest in integrated technologies, whether by internal development, partnerships, or acquisitions, to anchor customer relationships and create data-driven value.

For Policymakers

International regulators and health ministries should recognize the global ripple effects of national policies. China’s VBP and the US shift to ASCs have international implications. There is a need for dialogue on convergent regulatory standards, supply chain security, and ensuring that technological progress translates into equitable patient access.

For Investors

Investor diligence must go beyond conventional product pipelines and balance sheets. Understanding the macro-environmental forces—procurement policies, trade dynamics, and technology convergence—will be critical to assessing long-term value creation. Companies that demonstrate adaptability and strategic foresight in these areas may outperform.

Future Outlook

Looking ahead to the next three to ten years, the medtech industry will likely undergo further transformation.

• Artificial Intelligence and Data Integration: AI will become woven into medical devices and workflows, enabling predictive analytics, personalized treatment planning, and improved operational efficiency. The integration of real-world data will accelerate, but also raise privacy and regulatory challenges.
• Emerging Markets: While China remains central, other emerging economies in Asia, Latin America, and the Middle East are developing their own procurement systems and industrial strategies. Medtech companies will need to tailor approaches to each region.
• Climate and Sustainability: Environmental, social, and governance (ESG) considerations will increasingly influence purchasing decisions and regulations. Manufacturers will be under pressure to reduce waste, energy use, and emissions across the product lifecycle.
• Global Governance: The international community may need to develop new frameworks to address medical technology access, cybersecurity, and data governance, particularly as devices become more connected.
• Reshaped Competition: The convergence of pharma and medtech, the rise of digital platforms, and the entry of technology companies into healthcare will blur traditional boundaries. Collaboration and competition across these sectors will intensify.

Companies that succeed will be those that can navigate these uncertainties with agility and that embed strategic analysis into their core decision-making processes.

Conclusion

The five trends examined here are not discrete items but threads in a tapestry of global change. From the redefinition of market economics in China to the rise of platform-based competition, medical technology is being reshaped by forces that extend far beyond the laboratory. For stakeholders—whether in boardrooms, government ministries, or investment committees—an understanding of these dynamics is essential. The future of the industry will belong to those who recognize that long-term success hinges not on individual products but on the ability to anticipate and adapt to structural transformation.

---

Key Takeaways

• Mainland China’s VBP expansion is redefining global pricing and accelerating domestic innovation, with multinationals adapting through portfolio restructuring and premium positioning.
• The shift to outpatient and ASC settings requires new commercial models and product designs aligned with site-of-care economics.
• Supply chain resilience has become a strategic differentiator, driving multi-region manufacturing and digital supply chain investments.
• GLP-1 therapies are reshaping care pathways for obesity and related conditions, creating both threats and opportunities for device manufacturers.
• Platform-based competition, enabled by robotics and digital technologies, is redefining how value is created and captured in medtech.

Sources:

• Clarivate - 5 medtech trends to watch in 2026